Sanli Y, et al. - In this retrospective study, researchers assessed the ability of quantitative ¹⁸F-FDG PET parameters to predict outcomes of patients with malignant melanoma (n = 34) who have been treated with immune modulation therapy. For all patients, the tumor heterogeneity [TH] index was calculated as the AUC value of a cumulative SUV volume histogram curve. Kaplan-Meier survival plots have been used, and Cox regression analysis has been conducted for predictors of survival. There were a total of 101 analyzed lesions. In patients with metastatic melanoma treated with immune modulation therapy as first-line or second-line therapy, the TH index was significantly related to overall survival.